Cardiff Oncology announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer. Dr. Kabbinavar will oversee the clinical development program for the company’s investigational drug onvansertib and will report directly to CEO, Mark Erlander, PhD.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly